ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
ASLAN Pharmaceuticals (NASDAQ: ASLN) will present a company update at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ASLAN Pharmaceuticals (NASDAQ: ASLN) will present a company update at the H.C. Wainwright Global Investment Conference from May 23 to 26, 2022. CEO Dr. Carl Firth will share insights on the company's innovative treatments targeting immunology. The presentation will be accessible starting May 24, 2022, at 7:00 AM ET for 90 days via the provided link and on ASLAN’s website. Additionally, ASLAN management is open to virtual one-on-one meetings during the conference. The company focuses on developing therapies for atopic dermatitis and autoimmune diseases.
Details
News Market Reaction – ASLN
The recorded move for ASLN in the trading session of this news was -0.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif. and SINGAPORE, May 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present a company update at the H.C. Wainwright Global Investment Conference. The conference will be held virtually and in-person from May 23 to 26, 2022.
The presentation will be available from Tuesday, May 24, 2022, at 7:00am ET for 90 days at this link and in the Investors section of ASLAN’s website.
ASLAN management will also be available for virtual one-on-one meetings throughout the conference. Please contact your representative at H.C. Wainwright to request a meeting.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.